Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells
Open Access
- 1 October 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (7), 2392-2398
- https://doi.org/10.1182/blood-2006-03-007468
Abstract
Purine nucleoside phosphorylase (PNP) deficiency in humans results in T lymphocytopenia. Forodesine, a potent inhibitor of PNP, was designed based on the transition-state structure stabilized by the enzyme. Previous studies established that forodesine in the presence of deoxyguanosine (dGuo) inhibits the proliferation of T lymphocytes. A phase 1 clinical trial of forodesine in T-cell malignancies demonstrated significant antileukemic activity with an increase in intracellular dGuo triphosphate (dGTP). High accumulation of dGTP in T cells may be dependent on the levels of deoxynucleoside kinases. Because B-cell chronic lymphocytic leukemia (B-CLL) cells have high activity of deoxycytidine kinase (dCK), we hypothesized that these lymphocytes would respond to forodesine. This postulate was tested in primary lymphocytes during in vitro investigations. Lymphocytes from 12 patients with CLL were incubated with forodesine and dGuo. These CLL cells showed a wide variation in the accumulation of intracellular dGTP without any effect on other deoxynucleotides. This was associated with DNA damage-induced p53 stabilization, phosphorylation of p53 at Ser15, and activation of p21. The dGTP accumulation was related to induction of apoptosis measured by caspase activation, changes in mitochondrial membrane potential, and PARP cleavage. Based on these data, a phase 2 clinical trial of forodesine has been initiated for CLL patients.Keywords
This publication has 40 references indexed in Scilit:
- ATR Activation Necessary But Not Sufficient for p53 Induction and Apoptosis in Hydroxyurea-Hypersensitive Myeloid Leukemia CellsCell Cycle, 2005
- ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2004
- Exploring Structure−Activity Relationships of Transition State Analogues of Human Purine Nucleoside PhosphorylaseJournal of Medicinal Chemistry, 2003
- Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777International Immunopharmacology, 2003
- Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to CisplatinJournal of Biological Chemistry, 2000
- Mutations in serines 15 and 20 of human p53 impair its apoptotic activityOncogene, 1999
- DNA damage activates p53 through a phosphorylation–acetylation cascadeGenes & Development, 1998
- One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside PhosphorylaseBiochemistry, 1998
- JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosisFEBS Letters, 1997
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972